Table 3.

Summary of adverse events reported in all R/R FL and DLBCL patients (safety population)

	R/R FL G-atezo-pola (N = 13)	R/R DLBCL R-atezo-pola (N = 21)
Patients with ≥ 1 AE, n (%)	13 (100.0)	17 (81.0)
Grade 3–5 AE, n (%)	8 (62.0)	5 (24.0)
Grade 5 (fatal) AE, n (%)	2 (15.0)a	1 (5.0)b
Serious AE, n (%)	4 (31.0)	2 (10.0)
AE leading to any drug discontinuation, n (%)	2 (15.0)	–
AE leading to pola dose reduction, n (%)	1 (8.0)c	–
AE leading to any dose interruption or modification, n (%)	6 (46.0)	3 (14.0)

AE adverse event, atezo atezolizumab, DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma, G obinutuzumab, pola polatuzumab vedotin, R rituximab, R/R relapsed/refractory

^aBronchopulmonary aspergillosis (n = 1) and unknown (n = 1)

^bPleural effusion (n = 1; a complication of sepsis)

^cPeripheral neuropathy (n = 1)